Iteos Therapeutics Inc (ITOS)

Mar 31, 2025

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Virtu Financial LLC - Defense World

Mar 31, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Sells 22,939 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

Mar 30, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Decreases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - The AM Reporter

Mar 30, 2025

Mar 28, 2025

Bank of New York Mellon Corp Sells 35,918 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

Mar 28, 2025

Mar 26, 2025

Iteos Therapeutics Inc Stock: Cancer Drug Pipeline Shows Promise - Sharewise

Mar 26, 2025

Mar 25, 2025

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewswire

Mar 25, 2025

Mar 25, 2025

Game-Changing Cancer Drug Data: iTeos Reveals Best-in-Class Antibody Results at AACR - Stock Titan

Mar 25, 2025

Mar 21, 2025

Long Term Trading Analysis for (ITOS) - news.stocktradersdaily.com

Mar 21, 2025

Mar 21, 2025

Victory Capital Management Inc. Has $782,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

Mar 21, 2025

Mar 17, 2025

US Bancorp DE Acquires 4,843 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

Mar 17, 2025

Mar 13, 2025

Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - Yahoo Finance

Mar 13, 2025

Mar 11, 2025

(ITOS) Investment Report - news.stocktradersdaily.com

Mar 11, 2025

Mar 10, 2025

Research Analysts Offer Predictions for ITOS Q1 Earnings - Defense World

Mar 10, 2025

Mar 09, 2025

Analysts Set Expectations for ITOS FY2029 Earnings - Defense World

Mar 09, 2025

Mar 08, 2025

Wells Fargo & Company Issues Pessimistic Forecast for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World

Mar 08, 2025

Mar 08, 2025

HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World

Mar 08, 2025

Mar 08, 2025

JPMorgan Chase & Co. Issues Pessimistic Forecast for iTeos Therapeutics (NASDAQ:ITOS) Stock Price - Defense World

Mar 08, 2025

Mar 07, 2025

iTeos Therapeutics: Poised for Success with Anti-TIGIT Therapies Amidst Competitive Landscape - TipRanks

Mar 07, 2025

Mar 07, 2025

iTeos Therapeutics (NASDAQ:ITOS) Earns Outperform Rating from Wedbush - Defense World

Mar 07, 2025

Mar 06, 2025

iTeos fait le point sur ses activités et publie ses résultats financiers pour le quatrième trimestre et l’exercice 2024 - GlobeNewswire Inc.

Mar 06, 2025

Mar 06, 2025

H.C. Wainwright maintains Buy on ITOS with $21 price target By Investing.com - Investing.com Canada

Mar 06, 2025

Mar 06, 2025

iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations - Simply Wall St

Mar 06, 2025

Mar 06, 2025

iTeos Therapeutics: Undervalued with Promising Pipeline and Strong Financial Position - TipRanks

Mar 06, 2025

Mar 06, 2025

Y Intercept Hong Kong Ltd Purchases Shares of 18,468 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

Mar 06, 2025

Mar 05, 2025

Iteos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 05, 2025

Mar 05, 2025

Iteos Therapeutics Inc expected to post a loss of $1.06 a shareEarnings Preview - TradingView

Mar 05, 2025

Mar 05, 2025

iTeos Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 05, 2025

Mar 05, 2025

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire

Mar 05, 2025

Mar 05, 2025

Can iTeos' $655M War Chest Deliver on Its Promising Cancer Immunotherapy Pipeline? - StockTitan

Mar 05, 2025

Mar 03, 2025

iTeos Therapeutics (ITOS) to Release Earnings on Wednesday - Defense World

Mar 03, 2025

Mar 01, 2025

ITOS stock touches 52-week low at $7.09 amid market challenges - MSN

Mar 01, 2025

Feb 28, 2025

(ITOS) Technical Pivots with Risk Controls - Stock Traders Daily

Feb 28, 2025

Feb 27, 2025

iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless - Seeking Alpha

Feb 27, 2025

Feb 25, 2025

Iteos Therapeutics stock hits 52-week low at $7.05 By Investing.com - Investing.com Canada

Feb 25, 2025

Feb 25, 2025

Iteos Therapeutics stock hits 52-week low at $7.05 - Investing.com India

Feb 25, 2025

Feb 25, 2025

Financial Contrast: enGene (NASDAQ:ENGN) versus iTeos Therapeutics (NASDAQ:ITOS) - Defense World

Feb 25, 2025

Feb 20, 2025

Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 5.2% - MarketBeat

Feb 20, 2025

Feb 20, 2025

Empowered Funds LLC Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

Feb 20, 2025

Feb 20, 2025

iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World

Feb 20, 2025

Feb 18, 2025

Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.2% - Defense World

Feb 18, 2025

Feb 17, 2025

(ITOS) Investment Analysis and Advice - Stock Traders Daily

Feb 17, 2025

Feb 16, 2025

Peapod Lane Capital LLC Invests $836,000 in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - MarketBeat

Feb 16, 2025

Feb 13, 2025

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by SG Americas Securities LLC - Defense World

Feb 13, 2025

Feb 06, 2025

When (ITOS) Moves Investors should Listen - Stock Traders Daily

Feb 06, 2025

Feb 04, 2025

We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully - Yahoo Finance

Feb 04, 2025

Feb 04, 2025

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Decline in Short Interest - MarketBeat

Feb 04, 2025